Ambio Pharmaceuticals

AmbioPharm is a leading global contract development and manufacturing organization (CDMO) specializing in the development and production of peptide-based pharmaceuticals. The company provides a full range of services, including custom peptide synthesis, process development, and large-scale cGMP manufacturing for clinical and commercial use. Beyond its CDMO operations, AmbioPharm maintains an internal pipeline of generic and proprietary peptide products focused on metabolic diseases and other therapeutic areas. With headquarters in South Carolina and major manufacturing facilities in Shanghai, the company utilizes advanced solid-phase and liquid-phase synthesis technologies. AmbioPharm supports a diverse client base ranging from virtual biotech firms to large multinational pharmaceutical companies. In 2018, a majority stake in the company was acquired by a private equity consortium led by TPG Capital.